Literature DB >> 4005119

Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.

P N Bennett, J Bennett, I Bradbrook, J Francis, V A John, H Rogers, P Turner, S J Warrington.   

Abstract

Oxprenolol was administered in single doses by mouth to healthy volunteers either in a polymer-matrix slow-release formulation (Slow Trasicor) or in osmotic drug-delivery systems (oxprenolol Oros). Plasma oxprenolol concentrations and heart rates after exercise were measured. Plasma concentrations of the drug were maximal at 3 h but negligible at 24 h after administration of Slow Trasicor. Following ingestion of the Oros systems measurable concentrations were maintained throughout 24 h. Significant reduction of exercise-induced tachycardia persisted for 24 h after administration of oxprenolol Oros. With Slow Trasicor heart rate responses had returned to baseline values by this time. The osmotic drug-delivery systems appear to sustain significant beta-adrenoceptor blockade for 24 h after a single oral dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005119      PMCID: PMC1463746          DOI: 10.1111/j.1365-2125.1985.tb02758.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.

Authors:  L Brunner; P Imhof; D Jack
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

4.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

  4 in total
  7 in total

1.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.

Authors:  M A van Baak; F T Verstappen; B Oosterhuis
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.

Authors:  A Racine-Poon; J Moppert
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.

Authors:  D B Jack; M J Kendall; S J Laugher; S R Smith
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

5.  Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.

Authors:  M J Bowles; N S Khurmi; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Concentration-effect relationships for oxprenolol in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.